Trial Profile
Agrylin Drug Use-Result Survey (Japan)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Anagrelide (Primary)
- Indications Essential thrombocythaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire
- 01 Oct 2022 Results (n=648 ) of subgroup analyses comparing patients with or without a history of cytoreductive therapy , age less than ot greater than 60 years and with an anagrelide starting dose of ≤0.5 mg/day or 1.0 mg/day, published in the International Journal of Hematology
- 20 Aug 2018 New trial record